These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1312 related items for PubMed ID: 10325453

  • 1. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
    Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT.
    Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
    [Abstract] [Full Text] [Related]

  • 2. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
    Rogers SL, Doody RS, Mohs RC, Friedhoff LT.
    Arch Intern Med; 1998 May 11; 158(9):1021-31. PubMed ID: 9588436
    [Abstract] [Full Text] [Related]

  • 3. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
    Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, Nishimura T.
    Dement Geriatr Cogn Disord; 2000 May 11; 11(6):299-313. PubMed ID: 11044775
    [Abstract] [Full Text] [Related]

  • 4. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
    Rogers SL.
    Dement Geriatr Cogn Disord; 1998 May 11; 9 Suppl 3():29-42. PubMed ID: 9853200
    [Abstract] [Full Text] [Related]

  • 5. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
    Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT.
    Neurology; 1998 Jan 11; 50(1):136-45. PubMed ID: 9443470
    [Abstract] [Full Text] [Related]

  • 6. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.
    J Am Geriatr Soc; 2001 Dec 11; 49(12):1590-9. PubMed ID: 11843990
    [Abstract] [Full Text] [Related]

  • 7. Donepezil for vascular cognitive impairment.
    Malouf R, Birks J.
    Cochrane Database Syst Rev; 2004 Dec 11; (1):CD004395. PubMed ID: 14974068
    [Abstract] [Full Text] [Related]

  • 8. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study.
    Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, Hunter J, Williams P.
    Int J Geriatr Psychiatry; 2011 May 11; 26(5):536-44. PubMed ID: 20872778
    [Abstract] [Full Text] [Related]

  • 9. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
    Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, Donepezil MSAD Study Investigators Group.
    Neurology; 2001 Aug 28; 57(4):613-20. PubMed ID: 11524468
    [Abstract] [Full Text] [Related]

  • 10. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials.
    Román GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ.
    Dement Geriatr Cogn Disord; 2005 Aug 28; 20(6):338-44. PubMed ID: 16192723
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM, Donepezil MSAD Study Investigators Group.
    Int J Geriatr Psychiatry; 2005 Jun 28; 20(6):559-69. PubMed ID: 15920715
    [Abstract] [Full Text] [Related]

  • 12. Donepezil for dementia due to Alzheimer's disease.
    Birks JS, Harvey RJ.
    Cochrane Database Syst Rev; 2018 Jun 18; 6(6):CD001190. PubMed ID: 29923184
    [Abstract] [Full Text] [Related]

  • 13. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, Xu Y, Murthy AK.
    Neurology; 2009 May 05; 72(18):1555-61. PubMed ID: 19176895
    [Abstract] [Full Text] [Related]

  • 14. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
    Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P, Donepezil MSAD Study Investigators' Group.
    Curr Med Res Opin; 2002 May 05; 18(6):347-54. PubMed ID: 12442882
    [Abstract] [Full Text] [Related]

  • 15. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study Group.
    JAMA; 2004 Jan 21; 291(3):317-24. PubMed ID: 14734594
    [Abstract] [Full Text] [Related]

  • 16. Goal setting and attainment in Alzheimer's disease patients treated with donepezil.
    Rockwood K, Graham JE, Fay S, ACADIE Investigators.
    J Neurol Neurosurg Psychiatry; 2002 Nov 21; 73(5):500-7. PubMed ID: 12397141
    [Abstract] [Full Text] [Related]

  • 17. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
    Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.
    Drugs Aging; 2008 Nov 21; 25(2):163-74. PubMed ID: 18257603
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.
    Black S, Román GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R, Donepezil 307 Vascular Dementia Study Group.
    Stroke; 2003 Oct 21; 34(10):2323-30. PubMed ID: 12970516
    [Abstract] [Full Text] [Related]

  • 19. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
    Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, Pourcher E, Gray J, Thomas G, Swartz J, Hsu T, Moline ML.
    Mov Disord; 2012 Sep 01; 27(10):1230-8. PubMed ID: 22915447
    [Abstract] [Full Text] [Related]

  • 20. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.
    Rockwood K, Fay S, Gorman M, Carver D, Graham JE.
    BMC Neurol; 2007 Aug 30; 7():26. PubMed ID: 17760991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.